Artificial Intelligence

With its stock under pressure, Geron will face investors to defend its RYTELO sales strategy and address delays in its pivotal myelofibrosis trial.

New federal initiatives are fast-tracking deep brain stimulation research, a move championed by Nexalin Technology that could revolutionize care for veterans.

America's power grid is at a breaking point. A new report reveals how homeowners and smart tech are forging a resilient, decentralized energy future.

Amid financial headwinds, CISO Global appoints a new EVP to accelerate AI innovation, enhance operational efficiency, and gain a competitive edge.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

Europe's largest cinema chain partners with Pixelworks, bringing motion-enhanced films to its premium screens to boost clarity and preserve artistic intent.

At a key industry summit, Sutro Biopharma showcases its next-gen ADC platform, designed to overcome treatment resistance with "supercharged" dual-payload drugs.

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

A Malaysian biotech's new study shows its NK cell therapy is safe, using a novel, low-cost method that could make advanced cancer treatment affordable worldwide.

Facing financial headwinds, network supplier DAVOLINK is merging with LoadRunner, pivoting to the booming but brutal AI-driven industrial automation market.

An international initiative uniting a Japanese firm, the UN, and Aikido masters empowers Los Angeles women with non-violent self-defense techniques.

AI firm DreamzTech Solutions gains major recognition, validating its AI-first strategy and signaling a new wave of Indian tech leaders on the global stage.

A brief delay in Avidity's stockholder vote signals the final, complex steps before its acquisition by Novartis and the launch of a new spin-off.

Pure Storage rebrands as Everpure and acquires 1touch, betting its future on providing the intelligent data management layer essential for enterprise AI.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

iRegene Therapeutics hits dual milestones, advancing AI-derived cell therapies for Parkinson's in the US and Multiple System Atrophy in China.

January data shows a massive jump in corporate financing requests, hinting at a busy year for investment, while the municipal market tells a different story.

Light Source Communications is building a massive underground dark fiber network to connect St. Louis and Tulsa, powering the AI revolution in the heartland.

A new initiative offers biotech firms free access to advanced epiproteomic analysis, aiming to accelerate the development of next-generation precision medicines.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.